ClinicalTrials.Veeva
Menu

Find clinical trials for Breast Cancer in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Triple Negative Breast Cancer
Cancer
Carcinoma
Endometrial Cancer
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Breast Cancer trials near Paris, Île-de-France, FRA:

Evaluation of Mobiderm Intimate Bra in the Management of Breast Edema Related to Breast Cancer Treatment (MOBIBRA)

The aim of this exploratory study is to assess the performance and tolerability of the MOBIDERM Intimate Bra in the management of breast ede ...

Enrolling
Breast Cancer Surgery
Device: Mobiderm Intimate Bra group
THUASNE

Paris, Paris 14, France

adjuvant systemic treatment instead of adjuvant chemotherapy followed by endocrine therapy in older patients with stage II-III ER+/HER2- early breast...

Active, not recruiting
Breast Cancer Stage II
Breast Cancer Stage III
Drug: Palbociclib
Drug: Docetaxel / cyclophosphamide

Phase 2

European Organisation for Research and Treatment of Cancer (EORTC)

Saint-Cloud, France and 72 other locations

non-metastatic early-stage triple-negative (TNBC) or HER2+ breast cancer. TNBC cohort is composed of 2 open-label, randomized arms,...

Enrolling
Breast Cancer
Drug: Bevacizumab
Drug: Pertuzumab

Phase 2

Gustave Roussy

Villejuif, France

Govitecan (SG) in locally advanced or metastatic triple-negative breast cancer where the disease has progressed despite chemotherap...

Enrolling
Metastatic Breast Cancer
Triple Negative Breast Cancer
Drug: Sacituzumab govitecan

Phase 3

Unicancer
Unicancer

Villejuif, France

This study aims to evaluate the efficacy and safety of U3-1402 in participants with advanced breast cancer (ABC). Participants have...

Active, not recruiting
Metastatic Breast Cancer
Advanced Breast Cancer
Drug: U3-1402

Phase 2

Gustave Roussy

Paris, France and 10 other locations

participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast...

Active, not recruiting
Breast Cancer
Locally Advanced Breast Cancer
Drug: Elacestrant Dihydrochloride
Drug: Samuraciclib

Phase 1, Phase 2

Carrick Therapeutics

Paris, France and 22 other locations

-positive / HER2-negative breast cancer which has spread beyond the original tumor and/or to other organs.During this stud...

Enrolling
Breast Cancer Recurrent
Drug: Standard endocrine therapy
Drug: Palbociclib 125mg

Phase 3

ETOP IBCSG Partners Foundation

Villejuif, France and 52 other locations

This is a phase II study, preceded by a safety run-in, with two independent cohorts (cohort A in early Triple Negative Breast Cancer...

Enrolling
Triple Negative Breast Cancer
Biological: Tumor samples analysis
Biological: Blood samples analysis: Circulating Tumor DNA

Phase 2

Institut Curie

Paris, France and 1 other location

Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer:A phase Ib/II, open-label, modular, dos ...

Enrolling
Breast Cancer
Drug: Durvalumab
Drug: Dato-DXd

Phase 1, Phase 2

Gustave Roussy

Villejuif, France

to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast...

Active, not recruiting
Estrogen Receptor Positive Breast Cancer
HER-2 Positive Breast Cancer
Drug: palbociclib
Drug: trastuzumab

Phase 3

Alliance Foundation Trials

Paris, France and 117 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems